ROK
34
-2
NRG
57
-2
CVX
58
-5
AEE
79
3
MMM
45
-4
RF
60
-4
AMZN
49
-6
SYK
37
-3
NAVI
32
-4
JCI
45
-4
MTB
49
-14
AMP
54
-3
DOW
28
-4
FLR
40
-8
MCO
64
-4
VTR
57
2
CTSH
42
-3
HUM
36
-4
ALLE
35
-6
FTI
68
-16
ROK
34
-2
NRG
57
-2
CVX
58
-5
AEE
79
3
MMM
45
-4
RF
60
-4
AMZN
49
-6
SYK
37
-3
NAVI
32
-4
JCI
45
-4
MTB
49
-14
AMP
54
-3
DOW
28
-4
FLR
40
-8
MCO
64
-4
VTR
57
2
CTSH
42
-3
HUM
36
-4
ALLE
35
-6
FTI
68
-16
Financhill
Back

X4 Pharmaceuticals 10K Form

Sell
28

XFOR
X4 Pharmaceuticals

Last Price:
$0.24
Seasonality Move:
14.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive XFOR News And Ratings

See the #1 stock for the next 7 days that we like better than XFOR

XFOR Financial Statistics

Sales & Book Value

Annual Sales: $2.6M
Cash Flow: $-33M
Price / Cash Flow: 0
Annual Sales: $0.13
Price / Book: 1.96

Profitability

EPS (TTM): -0.19000
Net Income (TTM): $-37.5M
Gross Margin: $1.8M
Return on Equity: -82%
Return on Assets: -23.56%

X4 Pharmaceuticals Earnings Forecast

Key X4 Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 3 years for XFOR is 68.83%.
  • The Selling, General & Administrative Expenses for XFOR have been equal to 2,405.87% of Gross Profit Margin.
  • The Research & Development expenses have been 3,192.92% of Revenue.
  • The Net Earning history of XFOR is -1,464.61% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 6 years.

X4 Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: XFOR
CUSIP: 98420X
Website: x4pharma.com

Debt

Debt-to-Equity Ratio: 3.41
Current Ratio: 3.41
Quick Ratio: 3.16

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

XFOR Technical Analysis vs Fundamental Analysis

Sell
28
X4 Pharmaceuticals (XFOR) is a Sell

Is X4 Pharmaceuticals a Buy or a Sell?